Is Dogwood Therapeutics, Inc. (DWTX) a Buy, Sell, or Hold?
NASDAQ : DWTX
Dogwood Therapeutics, Inc. — News
$1.84 USD
$0.04 (2.22%)
- Volume
- 51K
- Average Volume
- 91.62K
- Market Capitalization
- $61.88M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $9.50
- Year Low
- $1.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.86
| Source | Headline |
|---|---|
|
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3% – What’s Next?
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) shares traded up 4.3% during trading on Monday. The stock traded as high as $1.74 and last traded at $1.71. Approximately 83,119 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 68,704 shares. The stock had previously closed at defenseworld.net - 2026-08-04 02:03:42 |
|
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026. globenewswire.com - 2026-07-20 08:30:00 |
|
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 globenewswire.com - 2026-06-30 08:45:00 |
|
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript seekingalpha.com - 2026-06-16 12:02:09 |
|
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package globenewswire.com - 2026-05-18 08:45:00 |
|
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - globenewswire.com - 2026-05-14 08:30:00 |
